All lobbying filings

THE MCMANUS GROUP

Lobbying for FULCRUM THERAPEUTICS · Rare disease biopharma company

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025

Lobbying activity 1

Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025. Priority review vouchers: Give Kids a Chance Act of 2025 (H.R. 1262/S.932)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.